Syros Pharmaceuticals Inc (SYRS)
0.3218
-0.04
(-10.59%)
USD |
NASDAQ |
Nov 14, 10:25
Syros Pharmaceuticals Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.474 |
| September 30, 2023 | 1.131 |
| June 30, 2023 | 0.5589 |
| March 31, 2023 | 0.382 |
| December 31, 2022 | 0.3182 |
| September 30, 2022 | 0.3136 |
| June 30, 2022 | 1.31 |
| March 31, 2022 | 0.6446 |
| December 31, 2021 | 0.4724 |
| September 30, 2021 | 0.3778 |
| June 30, 2021 | 0.3069 |
| March 31, 2021 | 0.265 |
| December 31, 2020 | 0.4368 |
| September 30, 2020 | 0.4292 |
| June 30, 2020 | 0.3147 |
| March 31, 2020 | 0.2556 |
| December 31, 2019 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
2.474
Maximum
Dec 2023
0.5877
Average
0.382
Median
Mar 2023
Debt to Equity Ratio Benchmarks
| Baxter International Inc | 1.688 |
| AbbVie Inc | 11.78 |
| Elanco Animal Health Inc | 0.6679 |
| Opus Genetics Inc | 0.00 |
| Entrada Therapeutics Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 85.00M |
| Total Liabilities (Quarterly) | 96.12M |
| Shareholders Equity (Quarterly) | -11.12M |